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Abstract
In patients with metabolic syndrome, body iron overload exacerbates insulin resistance, impairment of glucose
metabolism, endothelium dysfunction and coronary artery responses. Conversely, iron depletion is effective to
ameliorate glucose metabolism and dysfunctional endothelium. Most of its effectiveness seems to occur through
the amelioration of systemic and hepatic insulin resistance.
In a study published by BMC Medicine, Michalsen et al. demonstrated a dramatic improvement of blood pressure,
serum glucose and lipids after removing 550 to 800 ml of blood in subjects with metabolic syndrome. This effect
was apparently independent of changes in insulin resistance, in contrast to previous cross-sectional and cohort
studies investigating the association between iron overload, insulin resistance and cardiovascular disease.
Despite drawbacks in the study design, its findings may lead the way to investigations aimed at exploring iron-
dependent regulatory mechanisms of vascular tone in healthy individuals and patients with metabolic disease, thus
providing a rationale for novel preventive and therapeutic strategies to counteract hypertension.
Please see related article: http://www.biomedcentral.com/1741-7015/10/54
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Background
Metabolic syndrome (MetS) is a clustering of cardiovas-
cular disease risk factors (for example, visceral, obesity
dyslipidemia, hypertension, hyperglycemia, fatty liver
disease). Both insulin resistance (IR) and low-grade
inflammation underlie the syndrome [1]. The presence
of MetS is predictive of type 2 diabetes mellitus
(T2DM) and all-cause mortality [2]. In the United
States, prevalence estimates of MetS are 33% for the
general younger adult population (aged 20 to 59) and
59% in older individuals. In the future, metabolic syn-
drome may overtake smoking as the leading risk factor
for heart disease [3]. Currently, it is possible to prevent
or delay the occurrence of MetS, mainly with a healthy
lifestyle, which is a lifelong commitment [1].
Other strategies are also possible. Michalsen et al. [4]
observed an impressive reduction of blood pressure
(about 18 mmHg in the treated group compared with
0.2 in the control group) in patients with MetS after
removing 550 to 800 ml of blood. The effect was evident
early after the first phlebotomy and persisted two weeks
following the second venopuncture (performed at Day
28). The study was a randomized, controlled single-
blinded trial of 64 hypertensive patients. Thirty-seven
percent had T2DM. Most of them were on drug treat-
ment. Changes in blood pressure and insulin resistance
(as estimated by the homeostatic model assessment of
insulin resistance, HOMA-IR) correlated with the reduc-
tion in ferritin levels.
The beneficial effects of phlebotomies have been
repeatedly observed in the past and documented in 1867
by Brunton, who observed that “Small bleedings of three
or four ounces, whether by cupping or venesection, were
(...) beneficial”, and recommended that a few ounces of
blood be removed every few weeks from patients with
angina. He attributed the relief of angina to the diminu-
tion of “arterial tension” [5]. In 1970, Parker et al. [6]
observed that angina was relieved and ventricular func-
tion returned to normal after a phlebotomy averaging
276 ml. More recently, iron overload was observed to
cluster with abnormalities of MetS, including overt
T2DM [7-9]. Iron depletion by repeated phlebotomies,
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erythrocytapheresis or use of iron chelators ameliorated
metabolic control, coronary artery responses and
endothelial dysfunction [7-9] and the beneficial effects of
these procedures on metabolism are thought to be driven
primarily by the amelioration of insulin resistance [9,10].
Puzzlingly, the beneficial effect on blood pressure
observed by Michalsen [4] was independent of any effect
on IR; hence, suggesting an independent mechanism of
action. The potential impact of the Michalsen’s study is
remarkable in terms of reduced health care costs. If
effectiveness of repeated phlebotomies in reducing blood
pressure in patients with MetS is confirmed, this could
dramatically reduce the burden of the syndrome and its
related costs. Indeed, phlebotomies as routine means for
primary prevention or treatment of hypertension are
easy to perform, low-in-cost and, hence, could be a
good alternative to more expensive drugs. Moreover, by
encouraging blood donation in patients with MetS it
will be effective also to respond to the worldwide signifi-
cant demand for red cells and blood components.
However, the results from this trial generate a number
of questions regarding the lack of effect on IR and the
early and consistent effects on blood pressure.
Iron overload, insulin resistance and risk of T2DM
A relationship between iron stores and IR has been
reported, but with some inconsistencies. The risk of dia-
betes was significantly lower in frequent blood donors
from the Health Professionals Follow-up Study when
compared with non-donors after 10 years of follow-up
[11]. However, the beneficial effect of frequent blood
donation disappeared at 12 years [12]. In the same cohort
[12] and in post menopausal women from the Iowa
Women’s Health Study [13], heme-iron intake from red
meat sources was associated with increased risk of
diabetes.
Serum ferritin, a surrogate marker of iron status as it
accurately reflects body iron stores in healthy individuals
[14], was associated with increased risk of T2DM [15].
Subjects with hyperferritinemia had a 2.4-fold higher risk
of developing T2DM [16]. This association was further
confirmed in other studies [17-19].
None of these aforementioned studies provided infor-
mation on insulin resistance, which has been explored in
cross-sectional investigations. Frequent blood donors had
improved insulin sensitivity and decreased insulin secre-
tion when compared with sporadic blood donors or non-
donors [20]. In an unblinded and uncontrolled study of
31 subjects with glucose intolerance, serial phlebotomy
individually adjusted to induce near iron deficiency was
associated with improved insulin sensitivity in response
to oral glucose loading and reduced levels of glycated
haemoglobin [21]. In another unblinded, randomized
study in 28 patients with high-ferritin T2DM, three serial
500-ml phlebotomies reduced mean serum ferritin from
460 to 232 ng/ml and simultaneously led to increased
insulin sensitivity and reduced levels of glycated haemo-
globin [8].
Concerning the relationship between iron stores, MetS
and IR, a number of epidemiological studies showed a
relationship [22-24]. Hence, the lack of a significant effect
of phlebotomies on IR in the present series is somewhat
unexpected. HOMA is a poor predictor of insulin sensi-
tivity in patients with T2DM, but, additionally, more
than two phlebotomies and steadily reduced ferritin
levels might be needed to see a significant effect of iron
depletion on IR in patients with long-term diabetes and
on multi-drug treatment as those evaluated in the
Michalsen’s series [4]. Indeed, significant effects after one
year of treatment in high-ferritin T2DM patients [7] and
after two years in those carrying hereditary hemochroma-
tosis [10] have been observed. Moreover, drug treatment
might have confounded results and thus, it would be
important to study in more depth the effects on HOMA-
IR by taking into account the use of medication (that is,
separating those taking metformin vs. the other groups).
Alternatively, the effects of blood donation on IR may
differ in subjects with normal versus abnormal glucose
tolerance as observed when exploring the effect of iron
depletion on brachial artery flow-mediated dilation [25]
and in keeping with those of Hirai et al. [26], who
demonstrated differential effects of vitamin C in subjects
with normal versus abnormal glucose tolerance.
Behind the iron-heart hypothesis
Several epidemiological studies have investigated the
effect of iron depletion on atherosclerosis, cardiovascular
risk, mortality and morbidity [27]. Blood pressure is one
of the main factors driving cardiovascular morbidity and
mortality, but no evidence was provided of any reduction
in blood pressure following phlebotomies.
By stratifying men from the Health Professionals Fol-
low-up Study according to lifetime number of donations
(0, 10 to 20 and ≥30), no difference was observed in the
risk for hypertension [11]. The Kuopio Study was the
study which reported significant differences in mean
blood pressures between donors and non-donors, but
such a difference might reflect different lifestyles [16].
Thus, one of the main questions is how two phlebo-
tomies worked to reduce blood pressure. Improvement
of IR is not a nominee, at least at a first glance. Michal-
sen et al. [4] argue that reduced low-grade inflammation
and oxidative stress may play a role as iron-dependent
hydroxyl radical formation can contribute to vascular
dysfunction. In this regard, high-frequency blood dona-
tion was associated with reduced serum ferritin and
increased brachial artery flow-mediated dilation com-
pared with low-frequency blood donation [22]. Serum
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ferritin was significantly decreased and flow-mediated
dilation was increased in high-frequency donors com-
pared with low-frequency donors with no between-
group difference in insulin sensitivity. The decrease in
flow-mediated dilation during oral glucose tolerance
testing did not differ between high- and low-frequency
blood donors [22]. Alternatively, the authors [4] specu-
late that changes in blood viscosity caused vasodilatation
and, in turn, reduced blood pressure.
On the other hand, as blood volume was not replaced
following phlebotomies, patients on multi-drug therapy
or with type 2 diabetes might also have a dysfunctional
endothelium and sympathetic response to relative hypo-
volemia. They might be unable to compensate for hypo-
volemia as healthy donors do. Indeed, most previous
evidence were from cohort and cross-sectional studies
of healthy donors [20], and from high-ferritin T2DM
patients and carriers of hereditary hemocromatosis in
whom blood volume was restored to normal at each
procedure [7,10].
Future directions and conclusions
The strength of Michalsen’s study is that for the first
time an effect of iron depletion on blood pressure is
recognized. Like other evidence from clinical studies,
the effectiveness of iron depletion on hypertension
needs to be proved with further studies. The focus of
the research should move toward two different fronts: i)
investigation of the effect of reducing body iron stores
through graded phlebotomy, preferably using solid mea-
sures of insulin sensitivity, vascular resistance, viscosity
and oxidative damage; ii) meta-analysis of data from
published cohorts or de novo analyses of much larger
cohorts of healthy donors and patients with an appro-
priately long-term follow-up and tight monitoring of
dietary iron intake.
In conclusion, findings from Michalsen’s study give
new perspectives for prevention and treatment of the
metabolic syndrome demonstrating that repeated phle-
botomies, a low-cost and minimally invasive technique,
are effective in reducing blood pressure with a mechan-
ism that is independent of insulin resistance. Routine
phlebotomies in these patients may enormously reduce
health care costs related to the epidemic metabolic syn-
drome and, importantly, also contribute to increase the
rate of blood donations.
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